Polymeric Micelles: Recent Advancements in the Delivery of Anticancer Drugs

Pharmaceutical Research

Volumn 33, Issue 1, 2016, Pages 18-39

  Gothwal, Avinash ^a   Khan, Iliyas ^a   Gupta, Umesh ^a  

^a CENTRAL UNIVERSITY OF RAJASTHAN   (India)

Author keywords

cancer; hydrophilic corona; hydrophobic core; nanotechnology; polymeric micelles

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CHITOSAN; COPOLYMER; CREMOPHOR; DOXORUBICIN; PACLITAXEL; POLOXAMER; POLY(BETA BENZYL ASPARTATIC ACID); POLYCAPROLACTONE; POLYLACTIC ACID; POLYMER; UNCLASSIFIED DRUG; WATER OIL CREAM; MICELLE;

ATOM TRANSFER RADICAL POLYMERIZATION; BIOCOMPATIBILITY; CANCER RESISTANCE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRON SPIN RESONANCE; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; MICELLE; MICROTUBULE; MOLECULAR WEIGHT; NANOTECHNOLOGY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERIZATION; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; SOLUBILIZATION; TUMOR VASCULARIZATION; ANIMAL;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MICELLES; NANOTECHNOLOGY; POLYMERS;

EID: 84952875387     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-015-1784-1     Document Type: Review

References (128)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 2011;339:974-84.
3. Yu JM, Li WD, Lu L, Zhou XY, Wang DY, Li HM, et al. Preparation and characterization of galactosylated glycol chitosan micelles and its potential use for hepatoma-targeting delivery of doxorubicin. J Mater Sci Mater Med. 2014;25:691-1.
4. Park TG, Yoo HS. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. J Control Release. 2001;70:63-70.
5. Park TG, Lee EA, Yoo HS. Doxorubicin-conjugated biodegradable polymeric micelles having acid-cleavable linkages. J Control Release. 2002;82:17-27.
6. Hami Z, Amini M, Khansari MZ, Rezayat SM, Gilani K. Doxorubicin-conjugated PLA-PEG-folate based polymeric micelle for tumor-targeted delivery: synthesis and in vitro evaluation. DARU J Pharm Sci. 2014;22-30.
7. Kataoka K, Matsumoto M, Yokoyama M, Okano T, Sakurai Y, Fukushima S, et al. Doxorubicin-loaded poly(ethylene glycol)-poly(b-benzyl-Laspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J Control Release. 2000;64:143-53.
8. Han M, Diao YY, Jiang HL, Ying XY, Chen DW, Liang WQ, et al. Molecular mechanism study of chemosensitization of doxorubicin-resistant human myelogenous leukemia cells induced by a composite polymer micelle. Int J Pharm. 2011;420:404-11.
9. Kataoka K, Kwon G, Naito M, Yokoyama M, Okano T, Sakurai Y. Block copolymer micelles for drug delivery: loading and release of doxorubicin. J Control Release. 1997;48:195-1.
10. Bae HY, Lee ES, Na K. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release. 2005;103:405-18.
11. Yin H, Bae YH. Physicochemical aspects of doxorubicin-loaded pH-sensitive polymeric micelle formulations from a mixture of poly(L-histidine)-b-poly(L-lactide)- b-poly(ethylene glycol). Eur J Pharm Biopharm. 2009;71:223-30.
12. Nasongkla N, Bey E, Ren J, Ai H, Khemtong C, Guthi JS, et al. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett. 2006;6:2427-30.
13. Nakanishu T, Fukushima S, Okamoto K, Suzuki M, Matsumura Y, Yokoyama M, et al. Development of the polymer micelle carrier system for doxorubicin. J Control Release. 2001;74:295-02.
14. Préat V, Danhier F, Magotteaux N, Ucakar B, Lecouturier N, Brewster M. Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for Paclitaxel. Eur J Pharm Biopharm. 2009;73:230-8.
15. Li J, Wang G, Zhao Y, Liu W. Synthesis and characterization of a novel polydepsipeptide contained tri-block copolymer (mPEG-PLLA-PMMD) as self-assembly micelle delivery system for paclitaxel. Int J Pharm. 2012;430:282-91.
16. Yao J, Zhou J, Dahmani FZ, Yang H, Zhang T, Zhan Q. Enhanced oral bioavailability of paclitaxel in pluronic/LHR mixed polymeric micelles: preparation, in vitro and in vivo evaluation. Eur J Pharm Sci. 2012;47:179-89.
17. Fang X, Sha X, Juan W, Li Y, Yuan S, Hao J, et al. Paclitaxel-loaded pluronic P123/F127 mixed polymeric micelles: formulation. Optimization and in vitro characterization. Int J Pharm. 2009;376:176-85.
18. Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Kim SW, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release. 2001;72:191-02.
19. Quin ZY, Wang Y, Wang C, Gong CY, Yang YJ, Gua G, et al. Polysorbate 80 coated poly (ε-caprolactone)-poly (ethylene glycol)-poly (ε-caprolactone) micelles for paclitaxel delivery. Int J Pharm. 2013;434:1-8.
20. Hennink WE, Soga O, Nostrum CF, Fens M, Rijcken CJF, Schiffelers RM, et al. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. J Control Release. 2005;103:341-53.
21. Park K, Jeong JH, Huh KM, Lee SC, Cho YW, Lee J. Hydrotropic polymer micelle system for delivery of paclitaxel. J Control Release. 2005;101:59-68.
22. Dhabolkar RD, Sawant RM, Mongyat DA, Devaranjan PV, Torchilin VP. Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux. Int J Pharm. 2006;315:148-57.
23. Li T, Han R, Wang M, Liu C, Jing X, Huang Y. Fusiform micelles from nonlinear poly(ethylene glycol)/polylactide copolymers as biodegradable drug carriers. Macromol Biosci. 2011;11:1570-8.
24. Liang N, Sun S, Li X, Piao H, Cui F, Fang L, et al. α-Tocopherol succinate-modified chitosan as a micellar delivery system for paclitaxel: preparation, characterization and in vitro/in vivo evaluations. Int J Pharm. 2012;423:480-8.
25. Park EK, Kim SY, Lee SB, Lee YM. Folate-conjugated methoxypoly(ethylene glycol)/poly(q-caprolactone) amphiphilic block copolymeric micelles for tumor-targeted drug delivery. J Control Release. 2005;109:158-68.
26. Park K, Acharya G, Kim S, Kim JY. Hydrotropic polymer micelles containing acrylic acid moieties for oral delivery of paclitaxel. J Control Release. 2008;132:222-9.
27. Kim SC, Yoon HJ, Lee JW, Yu J, Park ES, Chi SC. Investigation of the release behavior of DEHP from infusion sets by paclitaxel-loaded polymeric micelles. Int J Pharm. 2005;293:303-10.
28. Hayama A, Yamamoto T, Yokoyama M, Kawano K, Hattori Y, Maitani Y. Polymeric micelles modified by folate-PEG-lipid for targeted drug delivery to cancer cells in vitro. J Nanosci Nanotechnol. 2007;8:1-6.
29. Opanasopit P, Yokoyama M, Watanabe M, Kawano K, Maitani Y, Okano T. Block copolymer design for camptothecin incorporation into polymeric micelles for passive tumor targeting. Pharm Res. 2004;21:2001-7.
30. Gao J, Blanco E, Bey EA, Dong Y, Weinberg BD, Sutton DM, et al. β-Lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells. J Control Release. 2007;122:365-74.
31. Kwon GS, Okano T. Polymeric micelles as new drug carriers. Adv Drug Deliv Rev. 1996;21:107-16.
32. Jones MC, Leroux JC. Polymeric micelles: a new generation of colloidal drug carriers. Eur J Pharm Biopharm. 1999;48:101-11.
33. Cabral H, Kataoka K. Progress of drug loaded polymeric micelles into clinical studies. J Control Release. 2014;190:465-76.
34. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003;2:347-60.
35. Khandare J, Minko T. Polymer-drug conjugates: progress in polymeric drugs. Prog Polym Sci. 2006;31:359-97.
36. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387-92.
37. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzym Regul. 2001;41:189-07.
38. Yokoyama M, Okano T, Sakurai Y, Ekimoto H, Shibazaki C, Kataoka K. Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res. 1991;51:3229-36.
39. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55:3752-6.
40. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A. 1998;95:4607-12.
41. Hashizum H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000;156:1363-80.
42. Bae Y, Jang WD, Nishiyama N, Fukushima S, Kataoka K. Multi-functional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery. Mol BioSyst. 2005;1:242-50.
43. Otsuka H, Nagasaki Y, Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev. 2003;55:403-19.
44. Bhadra D, Bhadra S, Jain P, Jain NK. Pegnology: a review of PEG-ylated system. Pharmazie. 2002;57:5-29.
45. Huh KM, Min HS, Lee SC, Lee HJ, Kim S, Park K. A new hydrotropic block copolymer micelle system for aqueous solubilization of paclitaxel. J Control Release. 2008;126:122-9.
46. Ping Q, Zhang C, Qu G, Yao Z, Wu X. PEG conjugated N-octyl-O-sulfate chitosan micelles for delivery of paclitaxel: in vitro characterization and in vivo evaluation. Eur J Pharm Sci. 2009;37:98-5.
47. Spencer CM, Faulds D. Paclitaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs. 1994;48:794-47.
48. Mekhail TM, Markman M. Paclitaxel in cancer therapy. Expert Opin Pharmacother. 2002;3:755-66.
49. Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer. 2000;88:2619-28.
50. Goldspiel BR. Clinical overview of the taxanes. Pharmacotherapy. 1997;17:110-25.
51. Weiss RB, Donehower RC, Wiernik PH. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8:1263-8.
52. Onetto N, Canett R, Winograd B, Catane R, Dougan M, Grechko J, et al. Overview of taxol safety. J Natl Cancer Inst Monogr. 1993;15:131-9.
53. Strieth S, Dunau C, Michaelis U, Jäger L, Gellrich D, Wollenberg B, et al. Phase I/II clinical study on safety and antivascular effects of paclitaxel encapsulated in cationic liposomes for targeted therapy in advanced head and neck cancer. Head Neck. 2014;36:976-84.
54. Liu Y, Sun J, Cao W, Yang J, Lian H, Li X, et al. Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery. Int J Pharm. 2011;421:160-9.
55. Teow HM, Zhou Z, Najlah M, Yusof SR, Abbott NJ, D'Emanuele A. Delivery of paclitaxel across cellular barriers using a dendrimer-based nanocarriers. Int J Pharm. 2013;441:701-11.
56. Zhang, Mei L, Feng SS. Paclitaxel drug delivery systems. Expert Opin Drug Deliv. 2013;10:325-40.
57. Cline EN, Li MH, Choi SK, Herbstman JF, Kaul N, Meyhöfer E, et al. Paclitaxel-conjugated PAMAM dendrimers adversely affect microtubule structure through two independent modes of action. Biomacromolecules. 2013;14:654-64.
58. Kannan V, Balabathula P, Divi MK, Thoma LA, Wood GC. Optimization of drug loading to improve physical stability of paclitaxel-loaded long-circulating liposomes. J Liposome Res. 2014;26:1-8.
59. Koudelka S, Turánek J. Liposomal paclitaxel formulations. J Control Release. 2012;163:322-34.
60. Matsumura Y. Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. Adv Drug Deliv Rev. 2008;60:899-14.
61. Zhang X, Jackson JK, Burt HM. Development of amphiphilicdiblock copolymers as micellar carriers of taxol. Int J Pharm. 1996;132:195-6.
62. Zhang X, Burt HM, Von Hoff D, Dexter D, Mangold G, Degen D, et al. An investigation of the anti-tumour activity and bio-distribution of polymeric micellar paclitaxel. Cancer Chemother Pharmacol. 1997;40:81-6.
63. Zhang X, Burt HM, Mangold G, Dexter D, Von Hoff D, Mayer L, et al. Anti-tumor efficacy and bio-distribution of intravenous polymeric micellar paclitaxel. Anti-Cancer Drugs. 1997;8:696-01.
64. Burt HM, Zhang X, Toleikis P, Embree L, Hunter WL. Development of copolymers of poly(D, L-lactide) and methoxypolyethylene glycol as micellar carriers of paclitaxel. Colloids Surf B: Biointerfaces. 1999;16:161-71.
65. Calley D, Autian J, Guess WL. Toxicology of a series of phthalate esters. J Pharm Sci. 1966;55:158-62.
66. Hill SS, Shaw BR, Wu AH. The clinical effects of plasticizers, antioxidants, and other contaminants in medical polyvinyl chloride tubing during respiratory and non-respiratory exposure. Clin Chim Acta. 2001;304:1-8.
67. Burt HM, Liggins RT. Polyether-polyester diblock copolymers for the preparation of paclitaxel loaded polymeric micelle formulations. Adv Drug Deliv Rev. 2002;54:191-2.
68. Wang Y, Wang C, Wang C, Gong CY, Wang Y, Guo G, et al. Polysorbate 80 coated poly (ε-caprolactone)-poly (ethylene glycol)-poly (ε-caprolactone) micelles for paclitaxel delivery. Int J Pharm. 2012;434:1-8.
69. Yoncheva K, Milanidova I, Calleja P, Agüreos M, Petrov P, Tsvetanov C, et al. Stabilized micelles as delivery vehicles for paclitaxel. Int J Pharm. 2012;436:258-64.
70. Zhao Y, Li J, Yu H, Wang G, Liu W. Synthesis and characterization of a novel polydepsipeptide contained tri-block copolymer (mPEG-PLLA-PMMD) as self-assembly micelle delivery system for paclitaxel. Int J Pharm. 2012;430:282-91.
71. Šmejkalová D, Nešporová K, Hermannová M, Angeles GH, Cožíková D, Vištejnová L. Paclitaxel isomerisation in polymeric micelles based on hydrophobized hyaluronic acid. Int J Pharm. 2014;466:147-55.
72. Knapczyk J, Krowczynski L, Krzck J, Brzeski M, Nimberg E, Schenk E, et al. Requirements of Chitosan for pharmaceutical and biomedical applications. Chitin and chitosan: sources, chemistry, biochemistry, physical properties and applications. London: Elsevier; 1989. p. 657-63.
73. Zhang C, Qu G, Sun Y, Wu X, Yao Z, Guo Q, et al. Pharmacokinetics, bio-distribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel. Biomaterials. 2008;29:1233-41.
74. Zhang C, Ding Y, Yu LL, Ping QN. Polymeric micelle systems of hydroxyl camptothecin based on amphiphilic N-alkyl-N-trimethyl chitosan derivatives. Colloids Surf B: Biointerfaces. 2007;55:192-9.
75. Miwa A, Ishibe A, Nakano M, Yamahira T, Itai S, Jinno S, et al. Development of novel chitosan derivatives as micellar carriers of Taxol. Pharm Res. 1998;15:1844-50.
76. Zhang C, Ping QN, Zhang HJ, Shen J. Preparation of N-alkyl-O-sulfate chitosan derivatives and micellar solubilization of Taxol. Carbohydr Polym. 2003;54:137-41.
77. Zhang C, Ping QN, Zhang HJ. Self-assembly and characterization of PTX-loaded N-octyl-O-sulfate chitosan micellar system. Colloids Surf B: Biointerfaces. 2004;39:69-75.
78. Zhang C, Qu G, Sun Y, Yang T, Yao Z, Shen W. Biological evaluation of N-octyl-O-sulfate chitosan as a new nano-carrier of intravenous drugs. Eur J Pharm Sci. 2008;33:415-23.
79. Gao Z, Lukyanov AN, Singhal A, Torchilin VP. Diacylpolymer micelles as nanocarriers for poorly soluble anticancer drugs. Nano Lett. 2002;2:979-82.
80. Gao Z, Lukyanov AN, Chakilam AR, Torchilin VP. PEG-PE/phosphatidylcholine mixed immunomicelles specifically deliver encapsulated taxol to tumor cells of different origin and promote their efficient killing. J Drug Target. 2003;11:87-92.
81. Minko T, Batrakova EV, Li S, Li Y, Pakunlu RI, Alakhov VY, et al. Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells. J Control Release. 2005;105:269-78.
82. Wang Y, Yu L, Han L, Sha X, Fang X. Difunctionalpluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and pluronic-mediated overcoming multidrug resistance in tumor cell lines. Int J Pharm. 2007;337:63-73.
83. Wang Y, Li Y, Wang Q, Wu J, Fang X. Pharmacokinetics and Biodistribution of paclitaxel loaded pluronic P105/L101 mixed polymeric micelles. Yakugaku Zasshi. 2008;128:941-50.
84. Dahmani FZ, Yang H, Yao J, Zhou J, Zhang T, Zhang Q. Enhanced oral bioavailability of paclitaxel in pluronic/LHR mixed polymeric micelles: preparation, in vitro and in vivo evaluation. Eur J Pharm Sci. 2012;47:179-89.
85. Liu Y, Zhang B, Yan B. Enabling anticancer therapeutics by nanoparticle carriers: the delivery of paclitaxel. Int J Mol Sci. 2011;12:4395-413.
86. Yahuafai J, Asai T, Nakamura G, Fukuta T, Siripong P, Hyodo K, et al. Suppression in mice of immunosurveillance against PEGylated liposomes by encapsulated doxorubicin. J Control Release. 2014;192:167-73.
87. Dicheva BM, Hagen TMLT, Schipper D, Seynhaeve ALB, Rhoon GCB, Eggermont AMM. Targeted and heat-triggered doxorubicin delivery to tumors by dual targeted thermos-sensitive cationic liposomes. J Control Release. 2014;195:37-48.
88. Xu H, Hu M, Yu X, Li Y, Fu Y, Zhou X, et al. Design and evaluation of pH-sensitive liposomes constructed by poly(2-ethyl-2-oxazoline)-cholesterol hemisuccinate for doxorubicin delivery. Eur J Pharm Biopharm. 2015;91:66-74.
89. Chang Y, Meng X, Zhao Y, Li K, Zhao B, Zhu M, et al. Novel water-soluble and pH-responsive anticancer drug nanocarriers: doxorucin-PAMAM dendrimer conjugates attached to superparamagnetic iron oxide nanoparticles (IONPs). J Colloid Intface Sci. 2011;363:403-9.
90. He H, Li Y, Jia XR, Du J, Ying X, Lu WL, et al. PEGylatedpoly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. Biomaterials. 2011;32:478-87.
91. Mastria ME, Chen M, McDaniel JR, Li X, Hyun J, Dewhirst MW. Doxorubicin-conjugated polypeptide nanoparticles inhibit metastasis in two murine models of carcinoma. J Control Release. 2015;208:52-8.
92. Zou Y, Liu P, Li CH, Zhi XT. Doxorubicin-loaded mesoporous magnetic nanoparticles to induce apoptosis in breast cancer cells. Biomed Pharmacother. 2015;69:355-60.
93. Kataoka K, Ishihara A, Harada A, Miyazaki H. Effect of block copolymer micelles as long- secondary structure of poly(L-lysine) segments on the micellization of poly(ethylene glycol)-poly(L-lysine) block co- polymer partially substituted with hydrocinnamoyl group at N-position in aqueous milieu. Macromolecules. 1998;31:6071-6.
94. Yokoyama M, Inoue S, Kataoka K, Yui N, Sakurai Y. Macromol. Preparation of adriamycin-conjugated poly(ethylene glycol)- poly(aspartic acid) block copolymer: a new type of poly- meric anticancer agent. Makromol Chem Rapid Commun. 1987;8:431-5.
95. Yokoyama M, Kwon GS, Okano T, Sakurai Y, Ekimoto H, Okamoto K, et al. Composition-dependent in vivo antitumor activity of adriamycin-conjugated polymeric micelle against murine colon adenocarcinoma 26. Drug Deliv. 1993;1:11-9.
96. Yokoyama M, Okano T, Sakurai Y, Kataoka K. Improved synthesis of adriamycin-conjugated poly(ethylene oxide)-poly(aspartic acid) block copolymer and formation of unimodal micellar structure with controlled amount of physically entrapped Adriamycin. J Control Release. 1994;32:269-77.
97. Kwon GS, Suwa S, Yokoyama M, Okano T, Sakurai Y, Kataoka K. Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly(ethylene oxide-aspartate) block copolymer-adriamycin conjugate. J Control Release. 1994;29:17-23.
98. Yokoyama M, Miyauchi M, Yamada N, Okano T, Sakurai Y, Kataoka K, et al. Polymer micelles as novel drug carrier: adriamycin-conjugated poly (ethylene glycol)-poly (aspartic acid) block co-polymer. J Control Release. 1990;11:269-78.
99. Kataoka K, Fukushima S, Miyata K, Bae Y, Nishiyama N. Smart polymeric micelles for gene and drug delivery. Drug Discov Today Technol. 2005;2:21-6.
100. Tsukioka Y, Matsumura Y, Hamaguchi T, Koike H, Moriyasu F, Kakizoe T. Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil). Jpn J Cancer Res. 2002;93:1145-53.
101. Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer. 2004;91:1775-81.
102. Lee ES, Na K, Bae YH. Polymeric micelle for tumor pH and folate-mediated targeting. J Control Release. 2003;91:103-13.
103. Jeong YI, Na HS, Cho KO, Lee HC, Nah JW, Cho CS. Antitumor activity of adriamycin-incorporated polymeric micelles of poly(gamma-benzyl L-glutamate)/poly(ethylene oxide). Int J Pharm. 2009;365:150-6.
104. Jeong B, Bae YH, Lee DS, Kim SW. Biodegradable block copolymers as injectable drug-delivery systems. Nature. 1997;28:860-2.
105. Yokoyama M, Satoh A, Sakurai Y, Okano T, Matsumura Y, Kakizoe T, et al. Incorporation of water-insoluble anticancer drug into polymeric micelles and control of their particle size. J Control Release. 1998;55:219-29.
106. Patankar N, Waterhouse D. Nano-particulate drug delivery systems for camptothecins. Cancer Ther. 2012;8:90-4.
107. Bala V, Rao S, Boyd BJ, Prestidge CA. Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38. J Control Release. 2012;172:48-61.
108. Cho H, Lai TC, Kwon GS. Poly(ethylene glycol)-block-poly(ε-caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer. J Control Release. 2013;166:1-9.
109. Blanco E, Bey EA, Dong Y, Weinberg BD, Sutton DM, Boothman DA, et al. β -Lapachone-containing PEG- PLA polymer micelles as novel nano-therapeutics against NQO1- overexpressing tumor cells. J Control Release. 2007;122:365-74.
110. Yasugi K, Nagasaki Y, Kato M, Kataoka M. Preparation and characterization of polymer micelles from poly (ethylene glycol)-poly (D, L-lactide) block copolymers as potential drug carrier. J Control Release. 1999;62:89-100.
111. Riley T, Govender T, Stolnik T, Xiong CD, Garnrtte MC, Illum L. Colloidal stability and drug incorporation aspects of micellar-like PLA-PEG nanoparticles. Colloids Surf B: Biointerfaces. 1999;16:147-59.
112. Huh KM, Lee SC, Cho YW. Lee J, Jeong JH, Park K. Hydrotropic polymer micelle system for delivery of paclitaxel. J Control Release. 2005;101:59-68.
113. Yoo HS, Lee EA, Park TG. Doxorubicin-conjugated biodegradable polymeric micelles having acid-cleavable linkages. J Control Release. 2002;82:17-27.
114. Lavasanifar A, Samuel J, Kwon GS. Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery. Adv Drug Deliv Rev. 2002;54:169-90.
115. Moretton MA, Glisoni RJ, Chiappetta DA, Sosnic A. Molecular implications in the nanoencapsulation of the anti-tuberculosis drug rifampicin within flower-like polymeric micelles. Colloids Surf B: Biointerfaces. 2010;79:467-79.
116. Zhang X, Zeng X, Liang X, Yang Y, Li X, Chen H, et al. The chemotherapeutic potential of PEG-b-PLGA copolymer micelles that combine chloroquine as autophagy inhibitor and docetaxel as an anti-cancer drug. Biomaterials. 2014;35:9144-54.
117. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophore-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res. 2004;10:3708-16.
118. Kim DW, Kim SY, Kim SW, Shin SW, Kim JS, Park K, et al. Multicenter phase II trial of Genexol-PM, a novel cremophore-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007;18:2009-14.
119. Ahn HK, Jung M, Sym SJ, Shin DB, Kang SM, Kyung SY, et al. A phase II trial of cremophore EL-free paclitaxel (Grnexol-PM) and gemicitabine in patient with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2014;74:277-82.
120. Hamaguchi T, Kato K, Yasui H, Morizane C, Ikeda M, Ueno H, et al. A phase and pharmacokinetic study of NK 105, a paclitaxel incorporating micellar nanoparticle formulation. Br J Cancer. 2007;97:170-6.
121. Matsumura Y. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles which is designed based on EPR effect. Adv Drug Deliv Rev. 2011;63:184-92.
122. Wilson RH, Plummer R, Adam J, Eatock MM, Boddy AV, Griffin M, et al. Phase I and pharmacokinetic study of NC-6004, a new platinum entity of cisplatin-conjugated polymer forming micelles. J Clin Oncol. 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2008;26:2573.
123. Matsumura Y. The drug discovery by nanomedicine and its clinical experience. Jpn J Clin Oncol. 2014;44:515-25.
124. Sutton D, Nasongkla N, Blanco E. Functionalized micellar system for cancer targeted delivery. Pharm Res. 2007;24:1029-46.
125. Lee HS, Chung HC, Im SA, Park YH, Kim CS, Kim SB, et al. Multicellular phase II trial of genexol-PM, a cremophore-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat. 2008;108:241-50.
126. Svenson S. Clinical translation of nanomedicines. Curr Opin Sol St M. 2012;1-7.
127. Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumor activity and reduce the neurotoxicity of paclitaxel. Br J Cancer. 2005;92:1240-6.
128. Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, et al. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer. 2005;93:678-87.